Artificial interferons for treatment of infections

Summary:

A German university offers chimeric mutants of interferon alpha 2 and other interferon alpha subtypes with improved antiviral activity for treatment of chronic or acute viral infections, bacterial or parasitic infections or tumour therapy. These interferons are characterized by a high biocompatibility. The university offers license agreements.

Reference: TODE20200519003

Country: Germany

Submitted: 19. 6. 2020

View Partnering Opportunity

Keywords

Technology: Cytology, Cancerology, Oncology; Pharmaceutical Products / Drugs; Virus, Virology/Antibiotics/Bacteriology

Market: Oncology; Other clinical medicine; Pharmaceuticals/fine chemicals

NACE: -

Technologické nabídky a poptávky zpracovává BIC Plzeň, partner sítě Enterprise Europe Network.